The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study

References

• de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144 Suppl 58: 33–36.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4:833–842.
   PubMed Web of Science ®Google Scholar
• Mental Health Foundation. See psoriasis: look deeper – recognizing the life impacts of psoriasis [Internet]. 2012; [cited 2018 Oct 30]. Available from: https://www.mentalhealth.org.uk/publications/see-psoriasis-look-deeper-recognising-life-impacts-psoriasis
   Google Scholar
• Anstey A, McAteer H, Kamath N, et al. Extending psychosocial assessment of patients with psoriasis in the UK, using a self-rated, web-based survey. Clin Exp Dermatol. 2012;37:735–740.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psoriasis: assessment and management of psoriasis. NICE Clinical Guideline [CG153] [Internet]. 2017; [cited Oct 30, 2018]. Available from: https://www.nice.org.uk/guidance/CG153
   Google Scholar
• AbbVie Limited. Humira 40 mg solution for injection in pre-filled pen: Summary of Product Characteristics [Internet]. 2018 [cited 2018 Oct 30]. Available from: https://www.medicines.org.uk/emc/product/7986
   Google Scholar
• National Institute for Health and Care Excellence. Adalimumab for the treatment of adults with psoriasis. NICE Technology Appraisal Guidance [TA146] [Internet]. 2008; [cited Oct 30, 2018]. Available from: https://www.nice.org.uk/guidance/ta146?unlid=8346068882016119175149
   Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   PubMed Web of Science ®Google Scholar
• Saurat J-H, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566.
   PubMed Web of Science ®Google Scholar
• van Lümig PPM, van de Kerkhof PCM, Boezeman JBM, et al. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol. 2013;27:593–600.
   PubMed Web of Science ®Google Scholar
• López-Ferrer A, Vilarrasa E, Gich IJ, et al. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169:1141–1147.
   PubMed Web of Science ®Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, et al. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral center. J Eur Acad Dermatol Venereol. 2012;26:1298–1303.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, et al. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral center. Br J Dermatol. 2010;163:859–862.
   PubMed Web of Science ®Google Scholar
• Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatolog Treat. 2012;23:203–207.
   PubMed Web of Science ®Google Scholar
• Armesto S, Coto-Segura P, Mayorga J, et al. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice. J Dermatolog Treat. 2015;26:49–53.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18:341–350.
   PubMed Web of Science ®Google Scholar
• Revicki D, Willian MK, Saurat J-H, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158:549–557.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• SF-12 Health Survey – Optum.com [Internet]. [cited Oct 30, 2018]. Available from: https://campaign.optum.com/optum-outcomes/what-we-do/health-surveys/sf-12v2-health-survey.html.
   Google Scholar
• Feldman SR, Fleischer AB, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. 1996;106:183–186.
   PubMed Web of Science ®Google Scholar
• Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29.
   PubMedGoogle Scholar
• Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK, Johnson AM. Cutaneous body image: empirical validation of a dermatologic construct. J Invest Dermatol. 2004;123:405–406.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719–726.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216:260–270.
   PubMed Web of Science ®Google Scholar
• Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–244.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–895.
   PubMed Web of Science ®Google Scholar
• Türel Ermertcan A, Temeltaş G, Deveci A, et al. Sexual dysfunction in patients with psoriasis. J Dermatol. 2006;33:772–778.
   PubMed Web of Science ®Google Scholar
• Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075–1082.
   PubMed Web of Science ®Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris–update 2015–short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–2294.
   PubMed Web of Science ®Google Scholar
• Hunter HJA, Hinz R, Gerhard A, et al. Brain inflammation and psoriasis: a [11 C]-(R)-PK11195 positron emission tomography study. Br J Dermatol. 2016;175:1082–1084.
   PubMed Web of Science ®Google Scholar
• Menter A, Augustin M, Signorovitch J, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62:812–818.
   PubMed Web of Science ®Google Scholar
• Fortune DG, Richards HL, Kirby B, et al. Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients’ well-being. Br J Dermatol. 2004;151:1219–1226.
   PubMed Web of Science ®Google Scholar
• Berthold-Losleben M, Himmerich H. The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology. CN. 2008;6:193–202.
   Google Scholar
• Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001;45:72–76.
   PubMed Web of Science ®Google Scholar
• Iskandar IYK, Ashcroft DM, Warren RB, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015;173:510–518.
   PubMed Web of Science ®Google Scholar